Cooley advised Alto Neuroscience, a company redefining psychiatry by leveraging individuals’ neurobiology to develop personalized and highly effective medicines and helping patients get better faster, on its $147.9 million initial public offering. Partners Div Gupta, Christina Roupas, Courtney Tygesson and Laurie Bauer led the Cooley team advising Alto.
Legal insight for the capital markets
Close